Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $636.1 million as the latest value for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 3.43% to $636.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Feb 2026, up 5.6% year-over-year, with the annual reading at $688.1 million for FY2025, 2.81% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $636.1 million at Nurix Therapeutics, down from $688.1 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $688.1 million in Q4 2025, with the low at $308.2 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $479.6 million, with a median of $459.3 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 32.9% in 2023, then soared 96.7% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $416.8 million in 2022, then dropped by 14.68% to $355.6 million in 2023, then soared by 88.23% to $669.3 million in 2024, then rose by 2.81% to $688.1 million in 2025, then dropped by 7.56% to $636.1 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $636.1 million, $688.1 million, and $522.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.